GlaxoSmithKline (GSK) agreed to acquire a clinical-stage drug from Chimagen Biosciences, a privately held Chinese biotechnology company. CMG1A46 is a dual CD19 and CD20...
07.07.2012
- Celgene is one of two companies discussing whether to bid for Human Genome Sciences, which seeks an alternative to a hostile offer by British drugmaker GlaxoSmithKline, a source...
